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External beam irradiation (mean 45 Gy, range 44-50.4)+ 
HDRBT (2 fractions of 5-6 Gy); Group 2: 59/153 HDRBT alone 
(4 fractions of 5-6 Gy). Chemotherapy: 26 patients (4 cycles 
of carboplatin+paclitaxel). Toxicity evaluation: RTOG scores 
for bladder and rectum and the objective criteria of LENT-
SOMA for vagina. Statistics: Chi-square and Fisher exact tests.  
Results: Mean age (years): Group 1: 65 (40-88); Group 2: 62 
(39-90). Mean follow-up (months): Group 1: 47.51 (8.64-
82.149); Group 2: 48.08 (11.99-96.66). VCR: Only 2 patients 
in Group 1 (2.12%) and no patients in group 2(0%). Toxicity: 
Early problems in Group 1 appeared in 5.3 % in rectum (G1-
2), 7.5% in bladder (G1-2) and 2.1% in vagina (G1); late 
problems appeared in 7.3 % in rectum (all G1-2 but 1 G3), 
1.1% in bladder (G1) and 27.7% in vagina (all G1-2 but 1 G4). 
Group 2: Early: 6.7% in bladder (G1-2), 6.6% in vagina (G1-2). 
Late toxicity: Only vaginal problems were observed in 21.7% 
(G1-2). Significant differences were only found in rectal 
toxicity between Group 1 and Group 2 (p=0.004). 
Conclusions: The present brachytherapy schedule for 
postoperative treatment of EC of 2 fractions of 5 Gy after EBI 
and 4 fractions of 5 Gy administered on a daily basis is a safe 
regime in terms of local control and toxicity. Similar results 
were found in a previous series with an increased number of 
fractions.  
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Purpose/Objective: In our Gynaecological Cancer Centre in 
Zagreb, Croatia, we treat annually with radical irradiation 
around 100 patients with cervical cancer. We start with 
chemo-irradiation (TD 45Gy/25fr with weekly Cisplatin 
40mg/m2), and afterwards we continue with high dose rate 
(HDR) intracavitary brachytherapy (Iridium 192 source, 
Flexitron afterloading machine). We usually prescribe 4x7Gy 
to point A, and for many years we did Manchester planning 
based on X ray images with dose restrictions to organs at risk 
(OR) according to ICRU (International Commission on 
Radiation Units) 38 recommendations. After attending two 
gynaecological GEC ESTRO courses in 3D brachytherapy and 
an ESTRO funded visit to Department of Brachytherapy at the 
Institute of Oncology Ljubljana, our objective was to 
introduce 3D brachytherapy practice to our Centre. We 
realized that our main challenge was imaging since we have 
CT simulator and no MRI at our Centre. After learning the 
principles of GTV (gross tumour volume) and HR CTV (high 
risk clinical target volume) contouring on MR images, we 
tried to implement them to CT images. What helped greatly 
was our own clinical practice of trans-vaginal ultrasound (TV 
US) measurements of cervical tumour before and after 
chemo-irradiation.  
Materials and Methods: To evaluate advantages of 3D 
brachytherapy planning over Manchester planning we did a 
pilot study on 10 patients with cervical cancer. After they 
received chemo-irradiation we performed our usual 
brachytherapy application with Rotterdam applicator 
(intrauterine tandem + ovoids). For each patient we obtained 
CT images and contoured HR CTV based on US measurements 
and gynaecological (GYN) GEC ESTRO working group 
recommendations. TV US offered width, height and thickness 
of the cervical tumour. 
 
 
 
For each patient we did Manchester plan and 3D plan with 
dose prescription to point A or D90 HR CTV (minimum dose 
delivered to 90% of the respective volume) accordingly. 
Planning was done on Nucletron’s Oncentra planning system. 
Dose restrictions to OR were according to ICRU points in 
rectum and bladder for Manchester planning and 2cc GEC 
ESTRO recommendations for rectum, bladder and sigma for 
3D brachytherapy planning.  
Results: With 3D planning we were able to increase 
prescription dose to D90 HR CTV, (especially in large 
tumours), while respecting restriction doses to OR. Unlike 
Manchester plan, we could also provide better protection of 
sigma. With Manchester planning, small tumour volumes had 
large doses in D90 HR CTV, but large tumour volumes were 
not as covered as in 3D planning. 
 
 
 
Conclusions: 3D brachytherapy planning offers better control 
of tumour coverage and protection of OR. The lack of MR 
image planning shouldn’t be an obstacle for the introduction 
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of 3D brachytherapy to clinical practice. Trans-vaginal 
ultrasound of cervical cancer offers width, height and 
thickness of cervical tumour and makes HR CTV contouring on 
CT images easier.  
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Purpose/Objective: To present the experience in the daily 
practice of a novel MRI compatible perineal template 
developed in our Department, able to support both: an 
intrauterine probe (SIU) (intracavitary component. IC) and 
titanium needles (TN. Interstitial component) for MRI-Guided 
brachytherapy (BT) applications, in gynecologic malignancies 
There are different manufactured templates for interstitial 
implants as 'Martinez Universal Perineal Interstitial Template' 
(MUPIT) with angled openings or the 'Syed' template. Two 
deficits are inherent to the previously commented currently 
commercially available templates: the IC being difficult to 
reach cervix in depth and the necessity to use CT for the 
dosimetry being both not compatible with MRI.  
Materials and Methods: The developed template, adapts the 
currently existing manufactured MR compatibles intrauterine 
tubes (Nucletron-Elekta) allowing the deliver a large central 
dose, and TN, also compatible with MRI, with the capacity to 
cover the disease in all directions in gynecologic 
malignancies. The template has been developed with the aid 
of Lorca Marín S.A, Murcia, Spain in the manufacturing 
process. In the MRI (General Electric 1,5 tesla) we use a T2 
sequence for delineation of CTV and organ at risk following 
the recommendations of GEC-ESTRO and a 3D radio-
frequency Spoiled Gradient recalled Echo (SPGR) sequence to 
recognized the applicator and TN (Figure). From April 2013 
until November 2014, we have done sixteen implants. 
Fourteen patients were diagnosed of locally advanced cervix 
carcinoma (CC) and 2 vaginal recurrences of papilar serous 
endometrial carcinoma. Median age 66 years (33-77 years). 
Nine were staged as IIB (Figo 2009), 2, IIIB and II IV b. 
Results: In the CC, BT have done after External beam 
radiotherapy (EBRT) over pelvis (median dose 50.4 Gy (48.6- 
53.7 Gy). All patients have received concomitant 
chemotherapy with EBRT. The dose administrated with BT 
have been 6 fractions of 4 Gy in four days in 14 patients, 6 
fractions of 4.25 Gy in one patient because the delay 
between RTE and BT due to comorbidities. The dose has been 
prescribed to IR CTV in all cases following recommendations 
of GEC-ESTRO due to the charactheristics of the interstitial 
implant. Median D90 to IR-CTV calculated with EQD2 in 
patients with locally advance CC (we have excluded the 2 
recurrences in vagina because they are different behavior 
disease) is 80,5 Gy (62-5-84,2) with a median D90 in organ at 
risk (OR): bladder of 77,4 Gy (60,5-90,8Gy) and 69,9 Gy in 
rectum (58,3-83,7 Gy). The median overall survival is 13 
months (2- 19 months) with three patients with local 
persistence after BT. All doses in OR are under limits of GEC 
ESTRO recommendations. 
Conclusions: This new template allows increasing the CTV of 
the BT procedures in locally advanced ginecological tumors in 
4D MRI based BT, improving the possibilities for a more 
adaptative dosimetry with lower doses in OR. 
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Purpose/Objective: Our previous interstitial brachtherapy 
(ISBT) experience was associated higher vaginal toxicities, 
especially for lower vaginal tumors, thus increasing our 
interest in minimizing vaginal wall dose. Previous guidelines 
for vaginal tolerance have been a point dose on the vagina 
wall from intracavitary brachytherapy. Advances in imaging 
and 3-D planning have allowed further investigation into 
volumetric dosimetry. The purpose of this study is to 
investigate whether altered dwell times for vaginal obturator 
needles can reduce the vaginal wall dose without 
compromising the target coverage. 
Materials and Methods: To evaluate dosimetric changes on 
the vaginal wall dose, a vaginal cancer patient with ISBT was 
selected as a patient case. For comparisons, phantom case 
was set up which has parallel needle position as a perfect 
implant with same needle position as patient case. Vaginal 
wall was contoured as 0.5 cm thick volume around the 
vaginal surface of the obturator. Geometric optimization was 
used to create homogenous dose distribution on both 
phantom and patient cases as an initial treatment plan (20 
Gy/4 fractions). To reduce high vaginal wall dose, five 
different plans was created with the modification of dwell 
times on the surface obturator needles relative to a central 
obturator needle. DVH evaluation was done on each plan to 
compare dosimetric parameters. 
Results: The V150% dose was much larger in patient case 
than the phantom case due to the non-parallel needles. The 
modification of dwell times for the vaginal surface needles 
significantly reduced the volume of vagina wall receiving the 
V150% dose from 77.6% to 57.8% and V175% dose from 57.5% 
to 20.2% in patient case. Figure shows dose profiles from the 
vaginal surface of the obturator to the entire target volume 
between the needles (lowest dose area) in the phantom case. 
Modification of using 0% obturator surface needles after 
geometric optimization (plan 3) and no dwell position for 
inner obturator surface needles at the time of geometric 
optimization (plan 4) have lowest vaginal wall dose without 
changing target volume coverage.  
Conclusions: To reduce high dose volume of the vaginal wall, 
we now routinely insert a needle into the central canal of the 
vaginal obturator and modify dwell times at the needles 
along the surface of vaginal obturator to reduce the volume 
of the vaginal wall from exceeding 150% prescription dose.  
 
